Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
Paola Roa, Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, E. de Stanchina, Michelle de Marchena, S. Auwardt, Shaza Sayed Ahmed, N. Bremer, Soo-Ryum Yang, Yangbo Feng, Chao Zhou, Norman Kong, Ruixia Liang, Haipeng Xu, Bin Zhang, A. Bardelli, Eneda Toska, Andrea Ventura, A. Drilon, Emiliano Cocco
British Journal of Cancer